- Home
- SCNI vs PSTV Comparison
SCNI vs PSTV Comparison
Compare SCNI & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- PSTV
- Stock Information
- Founded
- SCNI 2003
- PSTV 1996
- Country
- SCNI Israel
- PSTV United States
- Employees
- SCNI N/A
- PSTV N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- PSTV Medical/Dental Instruments
- Sector
- SCNI Health Care
- PSTV Health Care
- Exchange
- SCNI Nasdaq
- PSTV Nasdaq
- Market Cap
- SCNI 1.9M
- PSTV 12.2M
- IPO Year
- SCNI N/A
- PSTV N/A
- Fundamental
- Price
- SCNI $2.76
- PSTV $0.64
- Analyst Decision
- SCNI
- PSTV Strong Buy
- Analyst Count
- SCNI 0
- PSTV 3
- Target Price
- SCNI N/A
- PSTV $12.75
- AVG Volume (30 Days)
- SCNI 22.4K
- PSTV 3.6M
- Earning Date
- SCNI 07-01-2025
- PSTV 05-19-2025
- Dividend Yield
- SCNI N/A
- PSTV N/A
- EPS Growth
- SCNI N/A
- PSTV N/A
- EPS
- SCNI 5.95
- PSTV N/A
- Revenue
- SCNI $658,000.00
- PSTV $5,824,000.00
- Revenue This Year
- SCNI N/A
- PSTV $13.26
- Revenue Next Year
- SCNI N/A
- PSTV $8.84
- P/E Ratio
- SCNI $0.47
- PSTV N/A
- Revenue Growth
- SCNI N/A
- PSTV 18.54
- 52 Week Low
- SCNI $1.90
- PSTV $0.24
- 52 Week High
- SCNI $8.92
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- SCNI 57.37
- PSTV 43.94
- Support Level
- SCNI $2.64
- PSTV $0.49
- Resistance Level
- SCNI $2.69
- PSTV $0.90
- Average True Range (ATR)
- SCNI 0.20
- PSTV 0.12
- MACD
- SCNI 0.09
- PSTV -0.01
- Stochastic Oscillator
- SCNI 88.24
- PSTV 18.48
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).